Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model
- 21 June 2008
- journal article
- research article
- Published by Elsevier in Neuroscience
- Vol. 155 (3) , 567-572
- https://doi.org/10.1016/j.neuroscience.2008.06.040
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Lithium delays progression of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2008
- The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neuronsMolecular Psychiatry, 2007
- Sodium Valproate Exerts Neuroprotective EffectsIn Vivothrough CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse ModelJournal of Neuroscience, 2007
- Concurrent Administration of Neu2000 and Lithium Produces Marked Improvement of Motor Neuron Survival, Motor Function, and Mortality in a Mouse Model of Amyotrophic Lateral SclerosisMolecular Pharmacology, 2007
- GSK-3 is a viable potential target for therapeutic intervention in bipolar disorderNeuroscience & Biobehavioral Reviews, 2007
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis miceJournal of Neurochemistry, 2005
- Benefit of valproic acid in suppressing disease progression of ALS model miceEuropean Journal of Neuroscience, 2004
- Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol.Stroke, 1987
- Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.Stroke, 1986
- Amphetamine, Haloperidol, and Experience Interact to Affect Rate of Recovery After Motor Cortex InjuryScience, 1982